tbuckley/cabot-search huggingface dataset:
FRI0617 Diagnostic sensitivity of cutoff values of IGG4-positive plasma cell number and IGG4-positive/CD138-positive cell ratio in typical multiple lesions of patients with IGG4-related disease
Authors: S Tsuge, I Mizushima, Y Fujisawa, S Hara, F Suzuki, K Ito, H Fujii, K Yamada, M Kawano
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Immunoglobulin G4-related disease (IgG4-RD) is a recently recognized systemic inflammatory disease with multi-organ involvement [1]. Diagnostically, two of the most important hallmarks of IgG4-RD are high IgG4-positive plasma cell (PC) counts and high IgG4/IgG ratios in affected organs. Although the International consensus statement (ICS) on the pathology of IgG4-RD adopted different IgG4-positive PC counts among affected organs for the diagnosis to differentiate IgG4-RD mimickers from IgG4-RD [2], histological and immunohistochemical findings of the specimens from not only one but multiple organs in the same patient has not been evaluated. <h3>Objectives</h3> This study aimed to investigate the diagnostic sensitivity of the cutoff values of IgG4-positive PC number and IgG4-positive/CD138-positive cell ratio proposed by the International consensus statement (ICS) on the pathology of IgG4-RD in typical multiple lesions of patients with IgG4-RD. <h3>Methods</h3> We evaluated IgG4-positive PC number and IgG4-positive/CD138-positive cell ratio in 35 samples from 16 IgG4-RD patients having more than two typical lesions of IgG4-RD. <h3>Results</h3> We evaluated twelve submandibular, eleven ophthalmic, four skin, four kidney, two pancreatic, and one bronchus and prostate lesion each in 16 patients with typical clinical, serological, and radiographic features. Concerning IgG4+ PC number per high power field, most ophthalmic (8/11), kidney (4/4), pancreatic (2/2), and bronchial lesions (1/1) fulfilled the cutoff value of ICS, whereas many of the submandibular (5/12) and skin lesions (0/4) did not. In contrast to the absolute number, almost all lesions fulfilled the cutoff value of IgG4+/CD138+ cell ratio. In five cases, only one or two lesions in the same patient fulfilled the cutoff value of ICS, while the others did not. <h3>Conclusions</h3> These results suggest that ICS criteria have different sensitivities among the affected organs in diagnosing IgG4-RD. <h3>References</h3> Stone JH, et al. IgG4-related disease. N Engl J Med. 2012;366:539–51. Deshpande V, et al. Consensus statement on the pathology of IgG4-related disease. Mod Pathol. 2012;25:1181–92. <h3>Disclosure of Interest</h3> None declared
SAT0731-HPR Symptoms of pain, fatigue and self-efficacy in young patients with spondyloarthritis – a comparison between women and men
Authors: A Torell, A Bremander, S Bergman, E Haglund
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Spondyloarthritis (SpA) often has an early disease onset with inflammatory back pain debuting already in young adulthood. Studies have shown gender differences in disease specific areas but few studies have focused only on the younger subjects. Extended knowledge based on self-reported information can help to better understand the characteristics of these younger women and men with SpA. <h3>Objectives</h3> To study the differences between young women and men with SpA with regard to self-reported pain measures, disease activity, fatigue, self-efficacy and health status. <h3>Methods</h3> A cross-sectional population based cohort of 201 patients age 18–36 years with SpA identified through a health care register by searching for ICD-10 codes for SpA between the years 2003–2007. They all responded to a questionnaire survey in 2009. 29% were diagnosed with ankylosing spondylitis, 39% with psoriatic arthritis, and 32% with undifferentiated spondyloarthritis. The survey included questions concerning pain (NRS 0–10 and a pain mannequin), fatigue (NRS 0–10), self-efficacy (ASES 10–100, low-high). The pain mannequin was used to categorize patients into groups; no chronic pain (NCP), chronic regional pain (CRP)or chronic widespread pain (CWP). Self-reported disease activity (BASDAI 0–10) and health status (EQ5D, 0–1) were used to describe the group. Characteristic symptoms are reported as mean, standard deviation (SD) and frequencies. T-test and Chi2 test were used to study gender differences. <h3>Results</h3> The mean age (SD) was, 30 (5) years, 60% were women. The group reported disease activity scores (BASDAI) of 3.8 (2.3), health status 0.75 (0.16), and a disease duration of 7 (5) years. One third were smokers or former smokers, and 69% reached WHO9s recommended level of health enhancing physical activity. 21% reported CRP, 41% CWP and the remaining 38% reported NCP. More women reported CWP pain than men, (48% vs. 30%, p=0.026). Women also reported worse pain compared to men, (3.9 (2.4) vs. 2.9 (2.1), p=0.001), worse fatigue (5.0 (2.6) vs. 3.9 (2.7), p=0.003), less self-efficacy for pain (53 (20) vs. 59 (21), p=0.040) and also for symptoms (59 (19) vs. 65 (20), p=0.038). <h3>Conclusions</h3> A significant proportion of both women and men reported symptoms consistent with chronic widespread pain already at young age. Women reported in general worse health compared to men, including pain distribution, pain intensity and pain management. This information could be valuable for clinicians in the care of young patients with SpA. <h3>Disclosure of Interest</h3> None declared
PDK4 Inhibits Cardiac Pyruvate Oxidation in Late Pregnancy
Authors: Laura X. Liu, Glenn C. Rowe, Steven Yang, Jian Li, Federico Damilano, Mun Chun Chan, Wenyun Lu, Cholsoon Jang, Shogo Wada, Michael Morley, Michael Hesse, Bernd K. Fleischmann, Joshua D. Rabinowitz, Saumya Das, Anthony Rosenzweig, Zoltan Arany
Journal: Circulation Research (2017)

Pregnancy profoundly alters maternal physiology. The heart hypertrophies during pregnancy, but its metabolic adaptations, are not well understood.To determine the mechanisms underlying cardiac substrate use during pregnancy.We use here 13C glucose, 13C lactate, and 13C fatty acid tracing analyses to show that hearts in late pregnant mice increase fatty acid uptake and oxidation into the tricarboxylic acid cycle, while reducing glucose and lactate oxidation. Mitochondrial quantity, morphology, and function do not seem altered. Insulin signaling seems intact, and the abundance and localization of the major fatty acid and glucose transporters, CD36 (cluster of differentiation 36) and GLUT4 (glucose transporter type 4), are also unchanged. Rather, we find that the pregnancy hormone progesterone induces PDK4 (pyruvate dehydrogenase kinase 4) in cardiomyocytes and that elevated PDK4 levels in late pregnancy lead to inhibition of PDH (pyruvate dehydrogenase) and pyruvate flux into the tricarboxylic acid cycle. Blocking PDK4 reverses the metabolic changes seen in hearts in late pregnancy.Taken together, these data indicate that the hormonal environment of late pregnancy promotes metabolic remodeling in the heart at the level of PDH, rather than at the level of insulin signaling.
AB0206 INTERLEUKIN-17 and CC-CHEMOKINE ligand 20 are not useful markers of rheumatoid arthritis activity in patients undergoing biologic treatment
Authors: D Sikorska, R Rutkowski, J Łuczak, W Samborski, J Witowski
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Interleukin-17 (IL-17) and IL-17-induced CC-chemokine ligand 20 (CCL20) are increasingly implicated in the pathogenesis of rheumatoid arthritis (RA). A correlation has been reported to exist between serum levels of IL-17 and CCL20 and the disease activity following biologic treatment [1]. However, such an effect has not been universally demonstrated [2]. <h3>Objectives</h3> The aim of the present study was to investigate if serum IL-17 and CCL20 reflect activity of the disease and whether they could be of prognostic value for predicting therapeutic response to biologic therapy in RA. <h3>Methods</h3> Thirty RA patients qualified to receive biologic treatment were prospectively assessed before and 12 weeks of therapy with either TNFα inhibitors or anti-IL-6 receptor antibodies. Serum concentrations of IL-17 and CCL20 were measured with high sensitivity ELISA with estimated detection levels 0.01 pg/ml and 0.47 pg/ml, respectively. Successful response to therapy was defined by the EULAR criteria. <h3>Results</h3> The patient baseline characteristics were summarized in Table 1. Twelve weeks of biologic treatment resulted in a significant improvement in the majority of the patients with only 2 patients (7%) identified as non-responders. The favorable response to therapy was reflected both by clinical and standard biochemical criteria (Table 2). However, the mean serum concentrations of IL-17 and CCL20 did not change significantly over the course of therapy and they did not correlate with the disease activity, response to therapy, the type of biologic intervention and other medication used. Serum IL-17 and CCL20 levels showed no correlation with DAS28, and standard inflammatory markers. <h3>Conclusions</h3> Serum levels of IL-17 and CCL20 did not parallel changes in the clinical status and standard biochemical parameters in patients undergoing biologic treatment for RA. Thus, the measurement of IL-17 and CCL20 in serum does not seem to provide additional information that would help to monitor the response to biologic treatment in RA more effectively. <h3>References</h3> Rosu A, Margaritescu C, Stepan A, et al.: IL-17 patterns in synovium, serum and synovial fluid from treatment-naive, early rheumatoid arthritis patients. Rom J Morphol Embryol 2012; 53(1):73–80. Silosi I, Boldeanu MV, Cojocaru M, et al.: The Relationship of Cytokines IL-13 and IL-17 with Autoantibodies Profile in Early Rheumatoid Arthritis. J Immunol Res. 2016;2016:3109135. <h3>Disclosure of Interest</h3> None declared
Reply: Pancreatic Tumors in Male Rats Elicited by Corn Oil Gavage
Authors: Joseph K. Haseman
Journal: JNCI Journal of the National Cancer Institute (1986)

Journal Article Reply: Pancreatic Tumors in Male Rats Elicited by Corn Oil Gavage Get access Joseph K. Haseman Joseph K. Haseman Biometry Branch, National Institute of Environmental Health Sciences, Mail Drop B3-02, P.O. Box 12233, Research Triangle Park, NC 27709 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 77, Issue 1, July 1986, Pages 305–307, https://doi.org/10.1093/jnci/77.1.305-a Published: 01 July 1986
AB0763 Ustekinumab for the treatment of psoriatic arthritis – results of the first interim analysis of the non-interventional study sustain
Authors: J Wendler, I Schwarze, H Schwenke, J Behrens, T Gruppe, F Behrens
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Objectives</h3> SUSTAIN is a prospective, multi-center non-interventional study in Germany to observe long term efficacy and safety, quality of life and further patient reported outcomes in patients with active psoriatic arthritis under treatment with Ustekinumab in routine clinical care. <h3>Methods</h3> In this study treatment with Ustekinumab is according to the label (Stelara®). It is planned to observe 400 patients at 75 centers for 160 weeks with documentation intervals at week 0 and 4 and then every 12 weeks. Besides demographic data, the following data will be documented: Amount of swollen and tender joints, tender entheses, skin symptoms (BSA and PASI), patient reported outcome concerning disease activity and pain, Health Assessment Questionnaire (HAQ), quality of life (SF-12), sleep quality (VAS), satisfaction with therapy of patient and physician, safety (adverse events [AE]/serious adverse events [SAE]), pharmacoeconomic aspects, number of patients with "Minimal Disease Activity" (MDA), number of patients with MDA at week 28 und 52. <h3>Results</h3> Overall, there have been 189 patients (56% women) at 59 centers documented after 11 months. At week 4 154 patients and at week 16 112 patients. At baseline, the patients had a mean age of 56 years (29–85), body weight 87 kg (50–147), BMI 30 (19–47), showed arthritis at small (68.8%) and/or big (51.3%) joints, skeletal involvement (19%), enthesitis (13.2%). The number of tender joints improved from a mean of 8,6 (CI 95% 7.1/10.2) to 4.7 (3.1/6.3) at week 16, number of swollen joints from 3,4 (2,6/4,2) to 1,4 (0.9/1.9). The patient reported global disease activity (0–100) decreased from 55.1 to 38.6 at week 16. Further improvements were documented for enthesitis, PSA, BSA, PASI, and pain. Efficacy of the therapy with Ustekinumab after 16 weeks was assessed as "very good" by 32.3% and as "good" by 44.8% of the treating physicians and by 34% and 40.2%, respectively, of the patients. In total, 60 adverse events were reported, of which four were serious. All in all safety of therapy with Ustekinumab after 16 weeks was assessed as "very good" by 51% and as "good" by 43.8% of the treating physicians, and by 55% and 37%, respectively, of the patients. <h3>Conclusions</h3> The non-interventional study SUSTAIN showed relevant improvements with elevated therapy satisfaction and good safety in patients with active psoriatic arthritis after 16 weeks under real world condition. <h3>Disclosure of Interest</h3> J. Wendler Consultant for: Janssen-Cilag GmbH, Speakers bureau: Janssen-Cilag GmbH, I. Schwarze: None declared, H. Schwenke: None declared, J. Behrens Employee of: Janssen-Cilag GmbH, T. Gruppe Employee of: Janssen-Cilag GmbH, F. Behrens Consultant for: Janssen-Cilag GmbH, Speakers bureau: Janssen-Cilag GmbH
THU0501 Efficacy and safety of methotrexate as maintenance therapy for children with anti–n-methyl-d-aspartate receptor (NMDAR) encephalitis: experience of a single center
Authors: D Ramos-Bello, AN Rangel-Botello, G Barragan-Pickens Aguilera, TA Luna-Zúñiga, AJ Pedro-Martínez, G Martínez-Flores, A Bravo-Oro, C Abud-Mendoza
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Autoimmune-mediated encephalitis (A-ME) in children remains as a diagnostic and therapeutic challenge (1). These patients have a 12% risk of relapse, which is usually more severe (2). We previously proposed the therapy with methotrexate (MTX) for this condition (3), and we are offering now additional data on its potential benefits. <h3>Objectives</h3> To describe the outcome of children with A-ME receiving MTX for at least one year after stabilization of symptoms. <h3>Methods</h3> In this retrospective study we recruited 11 patients (7 females) with A-ME, a mean age of 7.5 years (range 8 months - 14 years), and with a median follow up of 22 months. In all cases, anti-NMDAR antibodies (subunit NR1) were detected in the CSF. Data from these patients were collected by consulting medical records. Relapse of encephalitis was defined as new onset of symptoms occurring after at least 2 months of remission, in the absence of other CNS disease. <h3>Results</h3> Patients presented with seizures (n=10), behavioral changes (n=11), psychosis (n=11), speech problems (n=10), and autonomic/breathing dysregulation (n=9). Patients were initially treated with methylprednisolone pulses (n=11), rituximab (n=6), intravenous immunoglobulins (n=4), cyclophosphamide (n=3) and MTX (n=11). Complete remission was observed in all cases, and maintenance therapy with MTX (10 mg/m<sup>2</sup> BSA) was started in all them, with gradual tapering until it was stopped. Interestingly, no relapses have been observed in any case during the mean follow up. One patient had mild oral ulcers and other showed mild elevation of liver enzymes; both events remitted after discontinuing the treatment for a couple of weeks. <h3>Conclusions</h3> Since relapses in patients with A-ME are a relatively frequent, the immunosuppressive therapy to prevent them is fully justified (4). Moreover, MTX therapy in pediatric patients is safe and usually well tolerated (3,5,6). The recommended dose is less than 15 mg/m<sup>2</sup> BSA or 1 mg/kg, with a maximal dose of 40 mg and with folic acid supplementation. In this regard, our study suggests that MTX administration (10 mg/m<sup>2</sup> BSA) during at least one year is a viable and effective therapy for maintenance treatment of A-ME. Accordingly, we did not detect relapses in the 11 patients studied with a median follow up time of 22 months and with an acceptable safety profile. <h3>References</h3> AlHakeem AS, et al. Neurosciences (Riyadh). 2017;22:67–68. Titulaer MJ, et al. Lancet Neurol. 2013;12:157–165. Bravo-Oro A, et al. Rev Neurol. 2013;57:405–410. Lin JJ, et al. Pediatr Neurol. 2014;50:574–80. Weibel L, et al. Br J Dermatol. 2006;155:1013–20. Li SC, et al. Arthritis Care Res. 2012;64:1175–1185. <h3>Disclosure of Interest</h3> None declared
SAT0721-HPR Exposure to passive smoking and ra risk; results from the swedish eira study
Authors: AK Hedström, L Klareskog, L Alfredsson
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Smoking has consistently been associated with increased risk of developing rheumatoid arthritis (RA). However, no studies have been performed investigating the effect of exposure to environmental tobacco smoke (i.e. passive smoking) on RA risk. <h3>Objectives</h3> The aim of this study was to estimate the influence of passive smoking on the risk of developing the two major subsets of RA, defined by anti-citrullinated protein antibodies (ACPA) status. <h3>Methods</h3> A population-based case-control study using incident cases of RA was performed in Sweden, and the study population in this report was restricted to include never smokers (589 cases, 1764 controls). The incidence of RA among never smokers who had been exposed to passive smoking was compared with that of never smokers who had never been exposed, by calculating the odds ratio with a 95% confidence interval employing logistic regression. <h3>Results</h3> No association was observed between exposure to passive smoking and RA risk (OR 1.0, 95% CI 0.8–1.2 for ACPA positive RA, and OR 0.9, 95% CI 0.7–1.2 for ACPA negative RA). No suggestion of a trend between duration of passive smoking and RA risk was observed. <h3>Conclusions</h3> No association was observed between exposure to passive smoking and RA risk, which may be explained by a threshold below which no association between smoke exposure and RA occurs. <h3>Acknowledgements</h3> The EIRA study was supported by grants from the Swedish Medical Research Council, the Swedish Council for Health, Working life and Welfare, King Gustaf V:s 80-year foundation, the Swedish Rheumatism Foundation, Stockholm County Council, the insurance company AFA, the EU-supported AutoCure and BeTheCure projects, and from the COMBINE (Controlling chronic inflammatory diseases with combined efforts) project. <h3>Disclosure of Interest</h3> None declared
Menopausal Hormone Therapy
Authors: Melissa McNeil
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THU0330 Mycobacterial cord factor analog induces high il-6 secretion and mincle receptor expression in patients with takayasu arteritis
Authors: N Gupta, J Kabeer Doss, H Mohan, R Goel, D Danda
Journal: Annals of the Rheumatic Diseases (2017)

<h3>Background</h3> Association between Takayasu Arteritis (TA) and Tubcerculosis (TB) has been in vogue for years. Scientific evidence for this association is limited. <h3>Objectives</h3> To study pro-inflammatory cytokine responses and mRNA expression in patients with TA on exposure to Trehalose-6,6-dibehenate (TDB), a synthetic analogue of mycobacterial cord factor in comparison with healthy controls. <h3>Methods</h3> Patients with type V TA satisfying 1990 ACR criteria and age and sex matched healthy controls were recruited. 10 ml blood was collected in heparin coated tube. PBMCs were separated by density gradient centrifugation. PBMCs were cultured with and without 5μg/ml and/or 50 μg/ml of TDB for 48 hours in RPMI medium at 5% co2 incubator. IL-6, TNF-αand IL-17 were measured in cell culture supernatant. RNA was extracted from the cells and quantification of gene expression was performed using sequence specific primers with SYBR green in Step One Plus™ Real-Time PCR Systems (Applied Biosystems). <h3>Results</h3> Twenty two TA patients and 21 age and sex matched healthy controls were recruited. Baseline characteristic of cases included median (range) age:26.5 years (15–49), male:femaleratio of 5:17, ITAS-CRP2010: 7 (1–26) and DEITAK: 7.5 (1–21). Both patients and controls showed response by secreting IL-6 and TNF-α upon stimulation withTDB. Relative induction of IL-6 was significantly higher in TA [31.88 (0.74–168)] as compared to healthy controls [1.931 (0.644–8.21); p&lt;0.002]. IL-17 was undetectable even upon TDB stimulation. Relative mincle expression was significantly upregulated by TDB in TA1.03 (0.623–1.346) fold, as compared to healthy controls 0.43 (0.36–0.57) fold (p&lt;0.05). Relative gene expressions of IL-6, IL-8, TNFα, IFN-gand BCL-10 were not significantly different between TA and healthy controls. <h3>Conclusions</h3> Stimulation with TDB led to higher secretion of IL-6 and increased mincle expression in PBMCs of TA patients as compared to healthy controls. <h3>Disclosure of Interest</h3> None declared